GLN-APREMILAST TABLET
Nchi: Kanada
Lugha: Kiingereza
Chanzo: Health Canada
Tabia za bidhaa
(SPC)
06-08-2021
Hati zingine za bidhaa hii hazipatikani kwa sasa, unaweza kutuma ombi kwa huduma ya wateja wetu na tutakuarifu mara tu tutakapopata.
Tuma ombi.
Tuma ombi.
Viambatanisho vya kazi:
APREMILAST
Inapatikana kutoka:
GLENMARK PHARMACEUTICALS CANADA INC.
ATC kanuni:
L04AA32
INN (Jina la Kimataifa):
APREMILAST
Kipimo:
30MG
Dawa fomu:
TABLET
Tungo:
APREMILAST 30MG
Njia ya uendeshaji:
ORAL
Vitengo katika mfuko:
15G/50G
Dawa ya aina:
Prescription
Bidhaa muhtasari:
Active ingredient group (AIG) number: 0156231002; AHFS:
Idhini hali ya:
APPROVED
Idhini ya tarehe:
2022-11-14
Tabia za bidhaa
_Pr_
_GLN-APREMILAST (Apremilast Tablets 10 mg, 20 mg, 30 mg) _
_Page 1 of 37_
PRODUCT MONOGRAPH
PR
GLN-APREMILAST
apremilast tablets
10 mg, 20 mg, and 30 mg
Selective Immunosuppressant
Glenmark Pharmaceuticals Canada Inc.
1600 Steeles Ave. West,
Suite 407, Concord, ON
L4K 4M2
Date of Preparation:
August 06, 2021
Submission Control No: 243974
_Pr_
_GLN-APREMILAST (Apremilast Tablets 10 mg, 20 mg, 30 mg) _
_Page 2 of 37_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION.................................................... 3
SUMMARY PRODUCT INFORMATION
........................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS..................................................................................................
4
WARNINGS AND PRECAUTIONS
.................................................................................
4
ADVERSE REACTIONS
..................................................................................................
7
DRUG INTERACTIONS
................................................................................................
11
DOSAGE AND ADMINISTRATION
.............................................................................
14
OVERDOSAGE..............................................................................................................
15
ACTION AND CLINICAL PHARMACOLOGY
............................................................. 15
STORAGE AND STABILITY
........................................................................................
18
DOSAGE FORMS, COMPOSITION AND
PACKAGING............................................... 18
PART II: SCIENTIFIC INFORMATION
........................................................................
20
PHARMACEUTICAL INFORMATION
.........................................................................
20
CLINICAL
TRIALS............................................................................
Soma hati kamili
